JOURNEY MEDICAL CORP (DERM) Stock Earnings & Estimates
USA - NASDAQ:DERM - US48115J1097 - Common Stock
9.19 USD
+0.35 (+3.96%)
9.03 USD
-0.16 (-1.74%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 73.67M 16.70% | 79.181M 7.48% | 56.134M -29.11% | 70.821M 26.16% | 102.88M 45.27% | 148.88M 44.71% | |
| EBITDA YoY % growth | -23.24M 28.29% | 4.837M 120.81% | -14.806M -406.10% | 6.197M 141.85% | 36.996M 497.00% | 83.044M 124.47% | |
| EBIT YoY % growth | -27.52M 21.10% | 1.07M 103.89% | -18.23M -1,803.74% | -3.234M 82.26% | 13.91M 530.15% | 41.518M 198.48% | |
| Operating Margin | -37.36% | 1.35% | -32.48% | -4.57% | 13.52% | 27.89% | |
| EPS YoY % growth | -1.68 37.14% | -0.18 89.29% | -1.02 -466.67% | -0.32 68.50% | 0.35 209.52% | 1.26 257.97% |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.04 77.50% | 0.05 135.70% |
| Revenue Q2Q % growth | 19.231M 31.46% | 22.904M 68.16% |
| EBITDA Q2Q % growth | 2.631M 683.37% | 5.825M 427.15% |
| EBIT Q2Q % growth | 196.177K 106.78% | 2.928M 226.26% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.16 5.88% | -0.11 | -0.05 | -49.39% |
| Q1 2025 Q2Q % growth | -0.18 66.04% | -0.24 | 0.06 | 25.70% |
| Q4 2024 Q2Q % growth | -0.15 -25.00% | -0.36 | 0.21 | 58.28% |
| Q3 2024 Q2Q % growth | -0.17 -121.25% | -0.15 | -0.02 | -12.99% |
| Q2 2024 Q2Q % growth | -0.17 41.38% | -0.15 | -0.02 | -16.28% |
| Q1 2024 Q2Q % growth | -0.53 7.02% | -0.24 | -0.29 | -121.11% |
| Q4 2023 Q2Q % growth | -0.12 80.00% | -0.08 | -0.04 | -53.45% |
| Q3 2023 Q2Q % growth | 0.80 240.35% | -0.16 | 0.96 | 606.01% |
| Q2 2023 Q2Q % growth | -0.29 32.56% | -0.34 | 0.05 | 15.13% |
| Q1 2023 Q2Q % growth | -0.57 -612.50% | -0.46 | -0.11 | -25.11% |
| Q4 2022 Q2Q % growth | -0.60 63.41% | -0.48 | -0.12 | -26.05% |
| Q3 2022 Q2Q % growth | -0.57 -278.12% | -0.40 | -0.17 | -40.88% |
| Q2 2022 Q2Q % growth | -0.43 | -0.26 | -0.17 | -64.25% |
| Q1 2022 Q2Q % growth | -0.08 | -0.32 | 0.24 | 74.70% |
| Q4 2021 Q2Q % growth | -1.64 | -0.42 | -1.22 | -289.00% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 15.009M 1.04% | 15.232M | -223K | -1.46% |
| Q1 2025 Q2Q % growth | 13.139M 0.84% | 12.296M | 843K | 6.86% |
| Q4 2024 Q2Q % growth | 13.62M -10.73% | 14.498M | -878K | -6.06% |
| Q3 2024 Q2Q % growth | 14.629M -57.64% | 14.675M | -46K | -0.31% |
| Q2 2024 Q2Q % growth | 14.855M -13.49% | 14.158M | 697K | 4.92% |
| Q1 2024 Q2Q % growth | 13.03M 6.69% | 14.38M | -1.35M | -9.39% |
| Q4 2023 Q2Q % growth | 15.257M -4.46% | 15.362M | -105K | -0.68% |
| Q3 2023 Q2Q % growth | 34.539M 114.26% | 17.216M | 17.323M | 100.62% |
| Q2 2023 Q2Q % growth | 17.172M -6.11% | 15.104M | 2.068M | 13.69% |
| Q1 2023 Q2Q % growth | 12.213M -47.58% | 16.501M | -4.288M | -25.99% |
| Q4 2022 Q2Q % growth | 15.97M -8.85% | 16.912M | -942K | -5.57% |
| Q3 2022 Q2Q % growth | 16.12M -17.80% | 18.006M | -1.886M | -10.47% |
| Q2 2022 Q2Q % growth | 18.29M 19.62% | 21.734M | -3.444M | -15.85% |
| Q1 2022 Q2Q % growth | 23.3M | 22.593M | 707K | 3.13% |
| Q4 2021 Q2Q % growth | 17.52M -60.66% | 20.808M | -3.288M | -15.80% |
| Q2 2021 Q2Q % growth | 15.29M 62.31% | % | ||
| Q2 2020 Q2Q % growth | 9.42M -85.87% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -25% | -600% | 0.32% | -22.73% |
| Revenue | 1.05% | -3.43% | 0% | -2.19% |